Indian Generics Cut Ozempic Prices 70% as Novo Nordisk Announces DKK15bn Buyback
Over 40 Indian drugmakers launched semaglutide generics priced 70% below Ozempic and Wegovy, with monthly treatments costing $7.99–$44.73 and planned rollouts in Canada, Brazil and Latin America, threatening Novo Nordisk’s share in a projected $100 billion obesity market. Novo Nordisk also initiated a DKK 15 billion share repurchase and secured FDA clearance for a higher-dose Wegovy.
1. Indian Generics Launch
Following semaglutide patent expiry in India, over 40 pharmaceutical companies introduced generic versions of Ozempic and Wegovy at roughly 70% lower prices, offering monthly treatments at $7.99–$44.73.
2. Global Expansion Plans
Manufacturers plan to expand these generics into Canada, Brazil and Latin America, intensifying competition as the obesity market is projected to reach $100 billion by 2030.
3. FDA Approval of Higher-Dose Wegovy
Novo Nordisk received FDA clearance for 3 mg and 4.5 mg dosages of Wegovy, broadening treatment options for patients and potentially boosting prescription volumes.
4. DKK 15 Billion Share Repurchase Programme
Novo Nordisk initiated a DKK 15 billion share buyback over a 12-month period beginning February 4, 2026, aiming to support its share price and signal confidence in its valuation.